Method for the diagnosis and prognosis of malignant diseases

Details Method for the diagnosis and prognosis of malignant diseases Method for the diagnosis and prognosis of malignant diseases

2008-03-04

2011-10-04

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S001110

Reexamination Certificate

active

08029784

ABSTRACT:
Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.

REFERENCES:
patent: 4474892 (1984-10-01), Murad et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4665897 (1987-05-01), Lemelson
patent: 5093246 (1992-03-01), Cech et al.
patent: 5192660 (1993-03-01), Reed-Gitomer
patent: 5545807 (1996-08-01), Surani et al.
patent: 5567595 (1996-10-01), Kok
patent: 5629197 (1997-05-01), Ring et al.
patent: 5736348 (1998-04-01), Goldenberg et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5925334 (1999-07-01), Rubin et al.
patent: 5932475 (1999-08-01), Bandman et al.
patent: 6048703 (2000-04-01), Siman et al.
patent: 6096532 (2000-08-01), Armstrong et al.
patent: 6165786 (2000-12-01), Bennett et al.
patent: 6291643 (2001-09-01), Zou et al.
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6325785 (2001-12-01), Babkes et al.
patent: 6339075 (2002-01-01), King et al.
patent: 6350452 (2002-02-01), Riss
patent: 6462189 (2002-10-01), Koide
patent: 6506559 (2003-01-01), Fire et al.
patent: 7357928 (2008-04-01), Bates et al.
patent: 2002/0028488 (2002-03-01), Singh et al.
patent: 2003/0194754 (2003-10-01), Miller et al.
patent: 2004/0132049 (2004-07-01), Bates et al.
patent: 2005/0026860 (2005-02-01), Lin et al.
patent: 2005/0053607 (2005-03-01), Bates et al.
patent: 2005/0187176 (2005-08-01), Bates et al.
patent: 2006/0258605 (2006-11-01), Luo et al.
patent: 2009/0017009 (2009-01-01), Bates et al.
patent: 2009/0226914 (2009-09-01), Bates et al.
patent: 2011/0065121 (2011-03-01), Bates et al.
patent: 762572 (1999-11-01), None
patent: 10037861 (2002-02-01), None
patent: 07 242566 (1995-09-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 97/22250 (1997-06-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/40480 (1998-09-01), None
patent: WO 99/06588 (1999-02-01), None
patent: WO 99/53057 (1999-10-01), None
patent: WO 00/61597 (2000-10-01), None
patent: WO 00/63250 (2000-10-01), None
patent: WO 01/32832 (2001-05-01), None
patent: WO 01/35093 (2001-05-01), None
patent: WO 01/68836 (2001-09-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/91787 (2001-12-01), None
patent: WO 02/12437 (2002-02-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 03/029277 (2003-04-01), None
patent: WO 03/008617 (2003-10-01), None
patent: WO 03/086174 (2003-10-01), None
patent: WO 03/087124 (2003-10-01), None
patent: WO 2004/003554 (2004-01-01), None
patent: WO 2005/035579 (2005-04-01), None
patent: WO 2009/088837 (2009-07-01), None
Rubanyi (Molecular Aspects of Medecine 2001 ;22:113-142).
Inder Verma (Nature Sep. 1997;389:239-242).
Theodore Friedmann (Scientific American Jun. 1997, p. 96-101.
Orkin and Motulsky NIH ad hoc committee Dec. 1995 http://www.nih.gov
ews/pane/rep.html, p. 1.
Gura (Science, v278, 1997, pp. 1041-1042).
Abaza, M.S.I, et al, “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: Demonstration with region 94-100 (antigenic site 3) of myoglobin”, Journal of Protein Chemistry, vol. 11, No. 5, pp. 433-444, (1992).
Agrawal, S, et al, “Antisense therapeutics: is it as simple as complementary base recognition?”, Mol Med Today, vol. 6, No. 2, pp. 72-81, (2000).
Aihara, M, et al, “The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate”, Cancer, vol. 75, No. 2, pp. 522-529, (1995).
Aihara, M, et al, “Frequency of apoptotic bodies positively correlates With Gleason grade in prostate cancer”, Hum Pathol, vol. 25, No. 8, pp. 797-801, (1994).
Ali, S, et al, “Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma”, Am J Respir Crit Care Med, vol. 163, No. 4, pp. 989-993, (2001).
Altman, S, “Nobel lecture. Enzymatic cleavage of RNA by RNA”, Biosci Rep, vol. 10, No. 4, pp. 317-337, (1990).
Alvarex-Gonzalez, R, et al, “Selective loss of poly(ADP-ribose) and the 85-kDa fragment of ply(ADP-ribose) polymerase in nucleoli during alkylation-induced apoptosis of HeLa Cells”, J Biol Chem., vol. 274, No. 45, pp. 32122-32126, (1999).
Anderson, H.J, et al, “Flow cytometry of mitotic cells”, Exp Cell Research, vol. 238, No. 2, pp. 498-502, (1998).
Andrade, F, et al, “Apoptosis in systemtic lupus erythematosus”, Rheumatic Diseases Clinics of North America, vol. 2, (2000).
Awang, G, et al, “Mode of dimerization of HIV-1 genomic RNA”, Biochemistry, vol. 32, No. 42, pp. 11453-11457, (1993).
Ballou, B, et al, “Three-Dimensional Imaging of Nucleolin Trafficking in Normal Cells, Transfectants, and Heterokaryons”, SPIE, vol. 2680, pp. 124-131, (1996).
Ballou, B, et al, “Tumor Detection and Visualization Using Cyanine Fluorochrome-Labeled Antibodies”, Biotechnol Prog, vol. 13, pp. 649-658, (1997).
Ballou, B, et al, “Tumor Labeling in Vivo Using Cyanine-Conjugated Monoclonal Antibodies”, Cancer Immunol Immunother, vol. 41, pp. 257-263, (1995).
Ballou, B, et al, Abstract of “Cyanine Fluorocrome-Labeled Antibodies in Vivo: Assessment of Tumor Imaging Using Cy3, Cy5, Cy5.5, and Cy7”, Cancer Detect Prey, vol. 22, No. 3, pp. 251-257, (1998).
Baran, N, et al, “The SV40 large T-antigen helicase can unwind four stranded DNA structures linked by G-quartets”, Nucleic Acids Research, vol. 25, No. 2, pp. 297-303, (1997).
Barton, C.M, et al, “Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression”, Br J Cancer, vol. 71, No. 3, pp. 429-437, (1995).
Bates, P.J, et al, “Antiproliferative activity of G-rich oligonucleotides correlates with protein binding”, The Journal of Biological Chemistry, vol. 274, No. 37, pp. 26369-26377, (1999).
Beedassy, A, et al, “Chemotherapy in advanced prostate cancer”, Semin Oncol, vol. 26, No. 4, pp. 428-438, (1999).
Beltinger, C, et al, “Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides”, J Clin Invest, vol. 95, No. 4, pp. 1814-1823, (1995).
Benimetskaya, L, et al, “Formation of a G-tetrad and higher order structures correlates with biological activity of the Re1A (NF-kappaB p65) ‘antisense’ oligodeoxynucleotide”, Nucleic Acids Research, vol. 25, No. 13, pp. 2648-2656, (1997).
Benton, B.M, et al, “A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeastSaccharomyces cerevisiaeis a praline rotamase localized to the nucleolus”, J Cell Biol, vol. 127, No. 3, pp. 623-639, (1994).
Bergsmedh, A, et al, “Horizontal transfer of oncogenes by uptake of apoptotic bodies”, Proc Natl Acad Science USA, vol. 98, No. 11, pp. 6407-6411, (2001).
Bergsmedh, A, et al, “Loss of the p21(Cip1/Waf1) cyclin kinase inhibitor results in propagation of horizontally transferred DNA”, Cancer Research, vol. 62, No. 2, pp. 575-579, (2002).
Bernardi, F.D, et al, “A prognostic model of survival in surgically resected squamous cell carcinoma of the lung using clinical, pathologic, and biologic markers”, Mod Pathol, vol. 10, No. 10, pp. 992-1000, (1997).
Bernstein, E, et al, “Role for a bidentate ribonuclease in the initiation step of RNA interference”, Nature, vol. 409, No. 6818, pp. 363-366, (2001).
Bharti, A.K, et al, “Identification of a nucleolin binding site in human topoisomerase I”, J Biol Chem, vol. 271, No. 4, pp. 1993-1997, (1996).
Biggiogera, M, et al, “Heterogeneous ectopic RNP-derived structures (HERDS) are markers of transcriptional arrest”, FASEB J, vol. 14, No. 5, pp. 828-834, (2000).
Biscotti, C.V, et al, “Apoptotic bodies: a consistent morphologic feature of endocervical adenocarcinoma in situ”, American Journal of Surgical Pathology, vol. 22, No. 4

Affiliated with

Also associated with

Rating

Method for the diagnosis and prognosis of malignant diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for the diagnosis and prognosis of malignant diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the diagnosis and prognosis of malignant diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4258059